Thawkar Baban S, Kaur Ginpreet
Department of Pharmacology, SPP School of Pharmacy & Technology Management, SVKM's NMIMS, V.L. Mehta Road, Vile Parle (W), Mumbai, 400056, India.
J Tradit Complement Med. 2023 Nov 11;14(3):287-299. doi: 10.1016/j.jtcme.2023.11.001. eCollection 2024 May.
Activating NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) is crucial in the pathogenesis of Alzheimer's disease (AD). A multimodal treatment intervention is the most feasible way to alter the course of AD progression. Hence, the current study was conducted to study the combination of betanin (BET) and virgin coconut oil (VCO) on NLRP3 regulation in aluminum chloride-induced AD in Wistar rats.
BET (100,200 mg/kg) and VCO (1, 5 g/kg) alone and in combination (BET 100 mg/kg + VCO 1 g/kg and BET 200 mg/kg + VCO 5 g/kg) were given orally for 42 days. On day 21 and 42nd, the behavioral test was performed to check the animal's cognition. Acetylcholinesterase (AChE) activity, oxidative stress markers, estimation of NLRP3 and IL-1β, and histological examinations were conducted in the hippocampus (H) and cortex (C).
Treatment with BET and VCO alone or combined improved behavioral characteristics (MWM and PA p < 0.0001; EPM p = 0.5184), inhibited AChE activity (C, p = 0.0101; H, p < 0.0001), and lowered oxidative stress in the brain. Also, combination treatment restored the levels of NLRP3 (C, p = 0.0062; H, p < 0.0001) and IL1β (C, p = 0.0005; H, p = 0.0098). The combination treatment significantly reduced the degree of neuronal degeneration, amyloid deposition, and necrosis in the brain tissue. The current study revealed that the combination strategy effectively controlled neuroinflammation via modulation of the NLRP3 inflammasome pathway, paving the way for the new treatment.
激活NLRP3(含核苷酸结合寡聚化结构域、富含亮氨酸重复序列和吡啉结构域的蛋白3)在阿尔茨海默病(AD)的发病机制中起关键作用。多模式治疗干预是改变AD病程最可行的方法。因此,本研究旨在探讨甜菜红素(BET)和初榨椰子油(VCO)联合应用对氯化铝诱导的Wistar大鼠AD模型中NLRP3调节的影响。
单独及联合给予BET(100、200mg/kg)和VCO(1、5g/kg)(BET 100mg/kg + VCO 1g/kg以及BET 200mg/kg + VCO 5g/kg),口服给药42天。在第2天和第42天进行行为测试以检查动物的认知能力。检测海马体(H)和皮质(C)中的乙酰胆碱酯酶(AChE)活性、氧化应激标志物、NLRP3和白细胞介素-1β(IL-1β)水平,并进行组织学检查。
单独或联合使用BET和VCO治疗可改善行为特征(水迷宫和旷场实验p < 0.0001;高架十字迷宫实验p = 0.5184),抑制AChE活性(皮质,p = 0.0101;海马体,p < 0.0001),并降低大脑中的氧化应激。此外,联合治疗可恢复NLRP3(皮质,p = 0.0062;海马体,p < 0.0001)和IL-1β(皮质,p = 0.0005;海马体,p = 0.0098)的水平。联合治疗可显著降低脑组织中神经元变性、淀粉样蛋白沉积和坏死的程度。本研究表明,联合治疗策略通过调节NLRP3炎性小体途径有效控制神经炎症,为新的治疗方法铺平了道路。